Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...
This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting. Lee M. Jampol, MD, will deliver the lecture “How to Describe New Diseases, the Same Skills ...
Kodiak announces new data from APEX study of KSI-101 ...
Q&A: Christine Kay on the REMAIN trial results for patients with retinitis pigmentosa ...
Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...
Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease ...
The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...
Diabetic Retinopathy | clinical | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...
An anchored matching-adjusted indirect comparison may aid therapeutic decision-making. A study comparing the efficacy of 2 drugs evaluated in phase 3 trials using an anchored matching-adjusted ...
The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.
This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果